Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$703 Mln
Revenue (TTM)
$305 Mln
Net Profit (TTM)
$-15 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
425.7
P/B Ratio
2.2
Industry P/E
54.26
EV/EBITDA
22.5
Div. Yield
0.2 %
Debt to Equity
1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
39,329,600
CFO
$121.34 Mln
EBITDA
$230.41 Mln
Net Profit
$17.29 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CryoLife Inc (CRY)
| -0.5 | 9.8 | -0.5 | -9.9 | -10.4 | 3.9 | 15.0 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
CryoLife Inc (CRY)
| -13.8 | -12.8 | -4.5 | 47.9 | 0.0 | 77.6 | -3.8 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CryoLife Inc (CRY)
|
20.3 | 703.2 | 305.0 | -15.1 | 1.3 | -5 | 425.7 | 2.2 |
| 0.1 | -- | 92.8 | -69.0 | -70.2 | -- | -- | 0.0 |
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary,... and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded Read more
Chairman, Pres & CEO
Mr. James Patrick Mackin
Exec. VP, COO & CFO
Mr. David Ashley Lee CPA, CPA
Headquarters
Kennesaw, GA
Website
The share price of CryoLife Inc (CRY) is $20.25 (NYSE) as of 24-Mar-2022 09:30 EDT. CryoLife Inc (CRY) has given a return of -10.36% in the last 3 years.
The P/E ratio of CryoLife Inc (CRY) is 425.71 times as on 24-Mar-2022, a 685 premium to its peers’ median range of 54.26 times.
The P/B ratio of CryoLife Inc (CRY) is 2.22 times as on 24-Mar-2022, a 25 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of CryoLife Inc (CRY) are Rs -- and Rs -- as of 02-Apr-2026.
CryoLife Inc (CRY) has a market capitalisation of $ 703 Mln as on 24-Mar-2022. As per SEBI classification, it is a Small Cap company.
Before investing in CryoLife Inc (CRY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.